9DO Stock Chart & Stats
€0.02
€0.00(0.00%)
At close: 4:00 PM EDT
€0.02
€0.00(0.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.06
Previous CloseN/A
Volume0.00
Average Volume (3M)83.00
Market Cap
€5.37M
Enterprise Value€8.51
Total Cash (Recent Filing)€1.59M
Total Debt (Recent Filing)€45.48K
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding192,435,550
10 Day Avg. Volume0
30 Day Avg. Volume83
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)3.82
Price to Sales (P/S)5.04
P/FCF Ratio-87.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthTTM revenue accelerated materially versus the prior year, signaling stronger product adoption and demand. Durable top-line growth gives the company scope to scale gross margin and spread fixed R&D and G&A costs, improving the probability of moving toward sustainable profitability.
Low LeverageVery low debt reduces refinancing and interest-rate risk and preserves financial flexibility. This structural strength supports continued R&D and commercialization spending without immediate solvency pressure, enabling strategic investments or opportunistic M&A over the medium term.
Material FCF ImprovementImproving free cash flow indicates progress in converting revenue into internally generated funds. A sustained FCF improvement reduces reliance on external financing, lowers dilution risk, and creates a clearer path to self-funded growth and durable operations over the next several quarters.
Bears Say
Negative Cash GenerationOngoing negative operating and free cash flow represent persistent cash burn and a structural funding requirement. Until operating cash flow turns sustainably positive, the company must rely on external capital or reserves, raising execution and dilution risks over the coming 2–6 months.
Persistent UnprofitabilityNegative operating profit and EBITDA show the business remains in an investment-heavy phase without demonstrated earnings scalability. Continued subpar margins (net margin ~ -30%) could prolong losses and pressure returns absent durable margin expansion or significant revenue leverage.
Balance-sheet VolatilityA prior period of negative equity and historical balance-sheet swings indicate vulnerability if losses persist. This structural volatility can impair access to favorable capital, increase cost of capital, and elevate the likelihood of dilutive financings during funding needs over the medium term.
Glow LifeTech News
9DO FAQ
What was Glow LifeTech’s price range in the past 12 months?
Glow LifeTech lowest stock price was <€0.01 and its highest was €0.06 in the past 12 months.
What is Glow LifeTech’s market cap?
Glow LifeTech’s market cap is €5.37M.
When is Glow LifeTech’s upcoming earnings report date?
Glow LifeTech’s upcoming earnings report date is Sep 01, 2026 which is in 32 days.
How were Glow LifeTech’s earnings last quarter?
Currently, no data Available
Is Glow LifeTech overvalued?
According to Wall Street analysts Glow LifeTech’s price is currently Overvalued.
Does Glow LifeTech pay dividends?
Glow LifeTech does not currently pay dividends.
What is Glow LifeTech’s EPS estimate?
Glow LifeTech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Glow LifeTech have?
Glow LifeTech has 192,435,550 shares outstanding.
What happened to Glow LifeTech’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Glow LifeTech?
Currently, no hedge funds are holding shares in DE:9DO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Glow LifeTech
Glow Lifetech Corp. is a biotechnology enterprise based in North America, dedicated to the development and marketing of nutraceutical and cannabinoid-derived products. The company is actively commercializing two core technologies: MyCell Enhanced technology, which facilitates the optimal delivery of nutrients for both nutraceuticals and cannabis, and a Cannabis Smart Consumption System, designed to help users and patients store, track, manage, and consume cannabis products effectively. Glow Lifetech possesses exclusive rights throughout North America for the production, sale, and distribution of a specific micellization technology, applicable to cannabis and hemp-derived ingredients, curcumin, Vitamin K, and iron. A key aspect of their operations involves the advanced processing of ingredients, converting certain vitamins, nutraceuticals, and cannabis extracts into micellized forms. This process significantly boosts the bioavailability of fat-soluble compounds, ensuring near 100% absorption into the body and enhancing their compatibility with water. The company, founded in 2018, is headquartered in Toronto, Canada.
Technical Analysis
COSCIENS Biopharma
―
Kane Biotech
―
Quest Pharmatech
―
PreveCeutical Medical
―
PharmAla Biotech Holdings, Inc.
―